In order to evaluate the relevance of basic science discoveries to human lung cancer, it has been and will continue to be necessary to obtain and analyze human tissues. The purpose of the Tissue Banks Core (TBC) ia to provide to SPORE investigators a large number of well preserved and well characterized tumors, dysplastic lesions, benign tissues, cell lines and cell and tissue fractions as well as relevant clinical information for laboratory study. Fixed, frozen and cultured tissue, serum, peripheral blood cells (PBC), urine and sputum from patients with lung cancer or at risk for lung cancer are collected through tissue procurement protocols of SPORE-affiliated institutions and the Southwest Oncology Group (SWOG). Tissue and cellular specimens are characterized as to cell type and cytogenetic and immunohistochemical marker expression by pathologists and technicians of the TBC. Microdissection and in vitro culture techniques are used to isolate and purify tumor cells and preneoplastic epithelium from contaminating stromal cells. DNA and RNA are extracted from tissue homogenates and purified cell populations and aliquoted for PCR-based procedures and blotting techniques. Inventories of tissues and cells and products prepared from these are maintained at storage sites both at Grand Junction St. Mary's Cancer Research Institute and the UCHSC. Clinical data regarding potential causative, hereditary and prognostic factors are linked in a centralized database to specimens characterized and prepared by the TBC and are available for correlation with information regarding specific specimens obtained in basic science programs. Both prospectively and retrospectively collected tissue samples and clinical information are tracked by the TBC. Tissue from invasive tumors and adjacent non- neoplastic lung tissue, pretreatment plasma and PBC from patients with these tumors are collected and processed from patients treated surgically at SPORE affiliated institutions. The TBC constitutes a unique national source of uniformly typed, staged, treated and observed tumors and preneoplastic lesions. The C permits the most efficient possible use of limited amounts of tissue available from patients with lung cancer. Materials collected by the TBC are available to SPORE and other approved and funded investigators on the basis of scientific review.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
DeHart, David N; Fang, Diana; Heslop, Kareem et al. (2018) Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol 148:155-162
Patil, Tejas; Smith, Derek E; Bunn, Paul A et al. (2018) The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 13:1717-1726
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156

Showing the most recent 10 out of 435 publications